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Abstract
Objectives To describe the effect of multidisciplinary care on survival
in women treated for breast cancer.
Design Retrospective, comparative, non-randomised, interventional
cohort study.
Setting NHS hospitals, health boards in the west of Scotland, UK.
Participants 14 358 patients diagnosed with symptomatic invasive
breast cancer between 1990 and 2000, residing in health board areas
in the west of Scotland. 13 722 (95.6%) patients were eligible (excluding
16 diagnoses of inflammatory cancers and 620 diagnoses of breast
cancer at death).
Intervention In 1995, multidisciplinary team working was introduced in
hospitals throughout one health board area (Greater Glasgow;
intervention area), but not in other health board areas in the west of
Scotland (non-intervention area).
Main outcomemeasures Breast cancer specific mortality and all cause
mortality.
Results Before the introduction of multidisciplinary care (analysed time
period January 1990 to September 1995), breast cancer mortality was
11% higher in the intervention area than in the non-intervention area
(hazard ratio adjusted for year of incidence, age at diagnosis, and
deprivation, 1.11; 95% confidence interval 1.00 to 1.20). After
multidisciplinary care was introduced (time period October 1995 to
December 2000), breast cancer mortality was 18% lower in the
intervention area than in the non-intervention area (0.82, 0.74 to 0.91).
All cause mortality did not differ significantly between populations in the
earlier period, but was 11% lower in the intervention area than in the
non-interventional area in the later period (0.89, 0.82 to 0.97). Interrupted
time series analyses showed a significant improvement in breast cancer
survival in the intervention area in 1996, compared with the expected
survival in the same year had the pre-intervention trend continued
(P=0.004). This improvement was maintained after the intervention was
introduced.
Conclusion Introduction of multidisciplinary care was associated with
improved survival and reduced variation in survival among hospitals.
Further analysis of clinical audit data for multidisciplinary care could
identify which aspects of care are most associated with survival benefits.
Introduction
Breast cancer is the commonest cancer in women worldwide.1
Its incidence has increased over several decades, while the death
rate has fallen because of improved survival.2 3 Survival has
probably improved because of a mixture of earlier detection of
the disease (both through screening and earlier symptomatic
presentation),4 biological changes that have made the disease
more susceptible to hormonal therapy,5 6 and improved
treatment.7
Treatment of cancer has increasingly been provided within
centralised, specialist multidisciplinary teams in Europe, the
United States, and Australia.8-12 These teams were established
after observational evidence identified better outcomes among
patients treated by specialists for various common cancers13,
such as an 11-17% reduction in risk of death among women
treated for breast cancer by specialist surgeons.14 However, it
remains unclear whether multidisciplinary care improves cancer
survival and whether the costs justify clinical benefits.15-18
Although attempts have been made to estimate the costs of
multidisciplinary teams,15we are not aware of comparisons with
costs for conventional care.
Although some evidence has shown improved outcomes in
cancer associated with the introduction of multidisciplinary
care,19-21 a recent systematic review of 21 studies (including five
on breast cancer) could not determine a causal relation between
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such care and cancer survival for three main reasons.18 Firstly,
the definition of multidisciplinary care was imprecise and
heterogeneous. Secondly, the outcomes of multidisciplinary
care could have indicated selection biases towards patients with
more favourable prognostic features rather than true treatment
effects. Thirdly, no adjustment was made for the confounding
effects of temporal improvements in survival that might have
occurred without the introduction of multidisciplinary care. For
example, none of the identified studies included a
contemporaneous comparison group.18
In the early 1990s, variations in survival among hospitals
managed by the Greater Glasgow health board were reported
to the director of public health (HJGB). The hospital with
highest survival had delivered care in a multidisciplinary
manner. As a result, multidisciplinary teams were formally
established in October 1995 throughout the Greater Glasgow
health board area, with the aim of improving survival and
minimising variations among hospitals. No substantial
reorganisation of breast cancer care took place in areas managed
by other health boards in the west of Scotland until 2000, when
national guidance was introduced.22
We aimed to determine whether the introduction of
multidisciplinary care affected the survival of womenwith breast
cancer. Multidisciplinary teams were introduced to Greater
Glasgow health board as an NHS Scotland area-wide policy to
improve the quality of care. Therefore, an experimental study
design, such as the randomisation of patients to hospitals
providing or not providing multidisciplinary care, would not be
possible. We compared an intervention area that had introduced
multidisciplinary care with neighbouring areas (without such
care), before and after the organisational change.We addressed
the limitations of previous studies,18 by defining the composition
of a multidisciplinary team at the outset, observing the effect
of care where no other model was available, and including a
contemporaneous comparison population to adjust for temporal
improvements in survival.
Methods
Design and patients
We did a retrospective, comparative, non-randomised,
interventional cohort study. From the Scottish Cancer Registry,
we selected data for all incident, symptomatic invasive breast
cancers (ICD-10, international classification of diseases (ICD),
10th revision, codes C50·1 to C50·9) diagnosed between 1
January 1990 and 31 December 2000 for residents of health
board areas in the west of Scotland. We obtained data from the
Scottish Cancer Registry, which is a comprehensive account of
all incident cancers gathered from pathology, hospital, and death
records, among other sources. The registry is linked, by
probability matching, to death records from the General Register
Office for Scotland and has a high level of accuracy.23 24 Patients
were grouped according to the health board of diagnosis. The
Greater Glasgow health board area (population 900 000) was
the intervention area, and areas managed by the remaining health
boards in the west of Scotland (1 600 000) comprised the
non-intervention area.
Data for tumour size was only available in the Scottish Cancer
Registry from 1997 onwards. If data were available, we grouped
tumour size.14 We calculated age at diagnosis for all patients,
and used four age groups: younger than 50 years, which is
considered to be a proxy for premenopausal status25; 50-64 years,
the age band at which patients would be invited for breast
screening; 65-79 years, elderly and post screening age; and 80
years and older. The oldest age group has been shown to have
survival equal to that of younger women after treatment of breast
cancer26; the most appropriate management in this age group
also remains unclear.27
We included patients if they were diagnosed with breast cancer
but had no other primary cancers, were resident in and attending
an NHS hospital managed by one of the health boards in the
west of Scotland, and were not diagnosed by the National Breast
Screening Programme. Tumours detected by screening
programmes are usually at earlier stages with better prognoses.
Although screen detected patients might have been diagnosed
by the programme throughout the west of Scotland, they were
treatedmainly in two hospitals managed by the Greater Glasgow
health board.
Multidisciplinary team intervention
In 1995, multidisciplinary team care for all patients with breast
cancer was introduced in the Greater Glasgow health board area
(intervention area), but not in the areas managed by other health
boards in the west of Scotland (non-intervention area). Five
multidisciplinary teams were formed in the intervention area,
each led by a specialist surgeon performing in excess of 50
operations for invasive breast cancer each year. In 1995, a
multidisciplinary teamwas defined as a groupwith the following
characteristics:
• Comprised specialist breast cancer surgeons, pathologists,
oncologists, radiologists, and specialist nurses
• Worked to evidence based guidelines, written by the
specialist breast surgeon whose patients had the highest
survival rates before reorganisation of care delivery (WDG)
• Held weekly formal meetings to discuss results and agree
on adjuvant treatment for individual patients
• Audited clinical activity and reported results at regular
intervals
• Lead clinicians from each team met regularly with the
director of public health (HJGB) to discuss audit results
throughout the area, with the aim to minimise deviations
from guidelines and variations in practice and improve
quality of care.
Doctors operating on small numbers outside the five main
centres were no longer allowed to manage patients needing care
for breast cancer. As a result, there was a degree of centralisation
of services. However, the geographical location of the hospitals
in the intervention area was such that patients did not have to
travel long distances to receive care.
No formal change in delivery of care was introduced in the
non-intervention area; patients continued to receive care along
more traditional approaches, with surgeons making unilateral
decisions regarding surgery and adjuvant treatment. In 1999,
Scottish guidance was issued on the reorganisation of cancer
care.22 In 2001-02, services throughout the country began to
form managed clinical networks, of which multidisciplinary
care was a component. Thus, there was unlikely to be a clear
difference in the use of multidisciplinary care within the west
of Scotland NHS area after 2000.
Socioeconomic circumstances
Socioeconomic status was inferred for all patients on the basis
of their area of residence at the time of diagnosis, using a
deprivation category score, which is a validated seven category
ordinal score that ranks all postcode sectors from 1 (most
affluent) to 7 (most deprived), using four census variables that
have been shown to best correlate with health outcomes: car
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ownership, male unemployment, occupational social classes IV
and V (semi-skilled and unskilled occupations, respectively),
and overcrowding.28 We grouped scores further into three
conventional categories: affluent (scores 1 and 2), intermediate
(3 to 5), and deprived (6 and 7).14 Data from the 1991 census
showed that 51% of people in the intervention area lived in areas
classified as most deprived (scores 6 and 7), compared with
18% of residents in the non-intervention area.29
Statistical methods
We used univariate analyses to examine differences in survival
trends between the intervention and non-intervention areas for
two time periods, from January 1990 to September 1995 and
from October 1995 to December 2000. Where appropriate, we
used χ2 and t tests to calculate any significant differences in age,
deprivation, and tumour size. If needed, we transformed data
to a log scale to satisfy the assumption for the t test.
We defined survival as time from incidence of breast cancer to
the earlier of date of death or date of censoring. Patients
diagnosed in the earlier period were censored at 30 September
2002 and those diagnosed in the later period were censored at
31 December 2007, to remove any effects of differential
follow-up times between the two periods. Deaths due to breast
cancer were classified as patients with a main cause of death
coded by the Scottish Cancer Registry as ICD-9 codes 174.1 to
174.9 or ICD-10 codes C50.1 to C50.9.
We did an analysis of an interrupted time series to investigate
the effect of the intervention while adjusting for trends in
survival before the intervention.30 Our analysis did not include
patients with a date of incidence in 1995, the year the
intervention was introduced. We used survival at five year
follow-up (after diagnosis) as the outcome measure.
We did multivariable analyses using Cox’s proportional hazards
models31 to examine differences in survival (adjusted for age,
deprivation, and year of incidence) between the intervention
and non-intervention areas for each time period. The analysis
also calculated outcomes in relation to breast cancer mortality
and all cause mortality.
We used funnel plots to compare five year survival between
hospitals. Funnel plots are control charts in which the event of
interest is plotted against a measure of its precision.32 Limits for
the funnel plots were based on Wilson’s formula for binomial
confidence intervals.33 We plotted breast cancer survival at five
years for each hospital against the number of patients diagnosed
with breast cancer in that hospital. To compare survival between
hospitals, only one investigator (DSM) knew the code indicating
which hospitals comprised the intervention and non-intervention
areas. Hospitals with fewer than 25 patients diagnosed in each
five year time period were excluded from the funnel plots. This
exclusion avoided the range of the y axis scale being too large
to distinguish differences between hospitals with larger volumes.
We did all analyses using Stata, version 11 software.
Results
Of 14 358 patients reviewed, we excluded 636; 16 patients were
diagnosed with inflammatory cancer (ICD for Oncology, 2nd
edition, code M8530/3; seven patients in the intervention area,
nine in the non-intervention area), and 620 were diagnosed only
at death (death certificate only; 182, 438). Of 13 722 women in
the study population, 6050 (44.1%) were in the intervention
area and 7672 (55.9%) in the non-intervention area. Table 1⇓
describes patient characteristics.
Age ranged from 18 to 100 years (mean 62.9 years, standard
deviation 14.9); t tests of transformed data showed that ages
were similar between the intervention and non-intervention
areas, both before and after introduction of the intervention. We
found a significant difference in deprivation (P<0.001) between
the intervention and non-intervention areas, both before and
after the intervention. However, deprivation had not changed
significantly in either area over time. In both time periods, more
patients in the intervention area than in the non-intervention
area lived in the most deprived areas. Data for tumour size was
available from 1997 onwards only; available data showed a
mean tumour size of 23.9 mm (standard deviation 14.4); t tests
of transformed data showed that tumour size was similar in both
the intervention and non-intervention areas.
Survival
By the end of the follow-up period (seven years from the end
of each time period), 4844 (35.3%) study patients had died of
breast cancer and 8301 (60.5%) had died overall. Breast cancer
survival at five years in the time period before introduction of
multidisciplinary care was 71.3% (n=2201) in the intervention
area and 73.6% (n=2881) in the non-intervention area. These
proportions rose to 79.2% (n=2346) and 75.9% (n=2853),
respectively, in the time period after the intervention was
introduced. Overall survival at five years in the earlier time
period was 59.9% (n=1849) in the intervention area and 61.5%
(n=2408) in the non-intervention area. These proportions rose
to 65.6% (n=1942) and 63.8% (n=2400), respectively, in the
later time period.
Our analysis using an interrupted time series was based on breast
cancer survival at five years and omitted patients with an
incident cancer in 1995 (fig 1⇓). The analysis showed a
significant improvement (P=0.004) in survival in the intervention
area in 1996, compared with the expected survival in that year
had the pre-intervention trend continued—that is, had the
intervention not been introduced. We saw no corresponding
improvement in survival among patients in the non-intervention
area (P=0.64). Overall survival also did not improve in 1996,
in either the intervention or non-intervention area. The
introduction of the multidisciplinary approach initially had a
significant positive impact on breast cancer survival at five
years, on incident cancers in 1996, and this impact was
maintained (fig 1). We saw a similar pattern in overall survival
at five years, but the changes were not significant.
Table 2⇓ shows the multivariable survival analyses, using a
Cox’s proportional hazards model, that was adjusted for age,
deprivation, and year of incidence.
Breast cancer mortality
Before multidisciplinary care was introduced in 1995, breast
cancer mortality was higher in the intervention area than in the
non-intervention area (hazard ratio 1.11, 95% confidence interval
1.00 to 1.20; table 2). After the intervention was introduced,
mortality was significantly lower in the intervention area than
in the non-intervention area (0.82, 0.74 to 0.91). Another Cox
model showed a significant interaction between time period and
intervention area (P<0.001), indicating that mortality differed
significantly between the intervention and non-intervention
areas over time. Subgroup analyses by age group showed that
the effect of the intervention was strongest in patients aged 80
years and older (P=0.001), and significant also in patients aged
65-79 years (P=0.01). We saw no significant effects in either
of the younger age groups.
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All cause mortality
We saw no significant difference in all cause mortality between
intervention and non-intervention areas in the earlier time period
before multidisciplinary care was introduced (hazard ratio 1.06,
95% confidence interval 0.98 to 1.14; table 2). However, in the
later time period, mortality was 11% lower in the intervention
area than in the non-intervention area (0.89, 0.82 to 0.97). As
with breast cancer mortality, the effect of the intervention on
all cause mortality differed significantly in both the intervention
and non-intervention areas (P=0.003). Subgroup analyses by
age group showed a less clear pattern for all cause mortality
than that seen for breast cancer mortality. However, the effect
of the intervention was most significant in patients aged 80
years or older (P=0.002); this effect was not seen in any other
age group.
Funnel plot analysis
We used funnel plots to compare breast cancer survival at five
years among hospitals before and after the introduction of the
intervention in 1995 (fig 2⇓). A separate funnel plot was created
for each time period. In the earlier time period, we plotted breast
cancer survival for eight hospitals in the intervention area, and
15 hospitals in the non-intervention area. The number of patients
diagnosed per hospital ranged from 30 to 881 in the intervention
area and from 26 to 682 in the non-intervention area. Overall
mean survival at five year follow-up was 70.3% (range
36.7-76.8% in the intervention area, 65.4-86.4% in the
non-intervention area). Three of eight hospitals in the
intervention area were below the 95% confidence limit and two
were above. None of the non-intervention hospitals was below
the 95% confidence limit but two were above.
In the later time period, we plotted breast cancer survival for
five hospitals in the intervention area, and 10 hospitals in the
non-intervention area. The number of patients diagnosed per
hospital ranged from 293 to 1025 in the intervention area and
from 155 to 775 in the non-intervention area. Overall mean
survival at five years during this period (77.0%) was higher
than that during the earlier time period, with less variation
among hospitals (range 78.5-80.2% in the intervention area,
69.6-80.6% in the non-intervention area). All hospitals in the
intervention area lay within the 95% confidence limit. One
hospital in the non-intervention area was above the 95%
confidence limit and three were below the limit.
Discussion
Main findings
We found that the introduction of teams providing
multidisciplinary care for the treatment of breast cancer was
associated with 18% lower breast cancer mortality at five years
and 11% lower all cause mortality at five years, compared with
similar patients treated in neighbouring areas over the same
time period. The introduction of this intervention was also
associated with a reduction in the number of hospitals treating
breast cancer, reduced variation in survival rates among
hospitals, and the reorganisation of breast cancer care away
from hospitals with the poorest survival outcomes. Our use of
a contemporaneous comparison group suggests that the benefits
of multidisciplinary care exceeded those that would otherwise
have occurred owing to ongoing improvements in treatment of
breast cancer.
The effect size was of a similar magnitude to that found by
Gillis and Hole between specialist and non-specialist breast
cancer surgeons.34 Before the introduction of multidisciplinary
teams in the present study, patients with breast cancer in the
intervention area were treated by a mixture of specialist and
non-specialist surgeons, so it might be expected that onlymodest
improvements in survival would have been achieved by
introducing surgery by specialists alone. Although evidence
suggests that better local and regional treatment of disease by
specialist surgeons explains some of their survival advantage,35
the survival advantage of treatment within a multidisciplinary
team is unlikely to be explained by surgical specialisation alone.
Our results suggest an “empirical induction period” in the
intervention area, during which survival continued to increase
sharply between 1996 and 1997.
Strengths and weaknesses of the study
This non-randomised intervention study compared an
experimental intervention with no intervention. Although it did
not have the strength of a randomised controlled trial, that study
design was no longer possible because of the prolific
introduction of the multidisciplinary approach of care. The
principal limitation of our study was that the observed
differences in survival after the introduction of multidisciplinary
care in the intervention area might have been due to selection
biases or confounding factors.
Although a few patients in our study might have died outside
the UK and had been assumed to be alive, we have no reason
to believe that this was more likely to occur in the intervention
area than the non-intervention area. Selection criteria were
applied in the same way to all health board areas—therefore,
differential selection of patients with less advanced disease in
the intervention area after September 1995 seems unlikely.
Indeed, where data for tumour size were available, patients in
the intervention area had similar sizes of tumours to those in
the non-intervention area.
We excluded all patients with screen detected cancers because
they were treated almost exclusively within the intervention
area, and such cancers tend to be less advanced and less
aggressive.36 It is possible that patients treated in the intervention
area presented with less advanced disease after September 1995.
However, we have no reason to suspect this and available data
do not support this explanation.
Women frommore affluent areas have consistently been shown
to have better survival from breast cancer than those from less
affluent areas,37 38 but the improvement was observed even after
adjusting for deprivation. Other concurrent changes in healthcare
services, not attributable to the intervention, could have occurred
after 1995. However, we are not aware of differences in
availability of diagnostic or treatment services between health
board areas in the west of Scotland in 1996-2000. No other
major interventions, either local or national, were introduced
during that time. We are not aware of any formal arrangements
to introduce multidisciplinary care in the non-intervention area
after 1995, but we do know that trainee surgeons in the
intervention area in the early 1990s took up consultant posts in
other parts of Scotland. Therefore, improvements in surgical
practice could have occurred in the non-intervention area as a
result of multidisciplinary working. Such an effect would
attenuate rather than increase the true effects of multidisciplinary
care, by introducing some misclassification of intervention and
non-intervention areas.
Strengths andweaknesses in relation to other
studies
Comparisons have beenmade between contemporaneous groups
of patients given multidisciplinary or conventional treatment,
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within the same geographical area.39 However, the
multidisciplinary approach probably selects patients with
different prognostic factors from the entire patient population,
introducing potential selection biases. Patients treated by a
multidisciplinary team are also likely to undergo more
investigations and be subject to additional clinical audits, so
that information about their health and outcomes might differ
systematically from those of patients not in multidisciplinary
care. These selection and information biases complicate
investigations into the true effects of multidisciplinary working.
Our study probably did not have these biases, because the
intervention was provided for all patients within a geographical
area and we obtained the same data from the Scottish Cancer
Registry for patients in both intervention and non-intervention
areas. We defined the composition and functions of
multidisciplinary teams and used the same selection criteria for
both areas, thus directly avoiding weaknesses of previous
attempts to determine the effects of multidisciplinary care.18
Owing to the lack of a precise definition of multidisciplinary
care, and the variation in provision of health services in countries
outside the UK our results could be difficult to generalise.
Implications for doctors and policy makers
Multidisciplinary care probably improves patient outcomes by
influencing various aspects of care. These factors include
adherence to guidelines and nurse education,40 increased surgical
volume and experience,41 and improved interdisciplinary
working.42 43Kingsmore and colleagues reported that the survival
benefits of treatment by a specialist surgeon in breast cancer
could be explained by better local and regional treatment, as
defined by the King’s Fund consensus statement.35 44 Although
multidisciplinary care is considered standard practice in many
countries, access to such care still varies.8 10 11 45 Our results
support the universal provision of cancer care by specialist,
multidisciplinary teams. Furthermore, significantly improved
survival was achieved among patients aged 80 years and older,
which could be an important explanatory element to support
the introduction of multidisciplinary care for cancer.
Unanswered questions and future research
Further work is needed to understand how the multidisciplinary
approach affects specific elements of breast cancer care, to
further improve the effective management of patients.We found
that the benefits of multidisciplinary working were greatest in
older patients. Since the intervention guidelines were not age
specific, they could have given surgeons and other team
members more confidence to actively treat older patients rather
than managing them conservatively.
We found that multidisciplinary team care for breast cancer was
associated with substantial improvements in survival compared
with those we might have expected to occur. The introduction
of multidisciplinary care led by specialist breast surgeons
performing more than 50 operations per year, resulted in a
degree of centralisation of care. Therefore, multidisciplinary
teams could increase efficiency by fostering more centralised
hospital care. Owing to a lack of data, we were unable to explore
the financial cost of multidisciplinary working in our analysis.
There is clearly scope for research in this topic; doctors and
policymakers alike would benefit from cost effectiveness studies
of multidisciplinary working, which could help inform
implementation of future programmes. Although
multidisciplinary care for cancer has become standard practice
in many countries, persisting variations in access to specialist
care need to be minimised.
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What is already known on this topic
Care by a specialist clinician is associated with improved cancer survival
Treatment of cancer has increasingly been provided within centralised, specialist multidisciplinary teams, but it remains unclear whether
such care has contributed to improvements in cancer survival
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Tables
Table 1| Age and socioeconomic characteristics of 13<thin>722 female patients with breast cancer in the west of Scotland, 1990-2000. Data
are no (%)
October 1995 to December 2000January 1990 to September 1995
Intervention group (n=2962)Non-intervention group (n=3759)Intervention group (n=3088)
Non-intervention group
(n=3913)
Age (years)
739 (24.9)823 (21.9)735 (23.8)853 (21.8)≤49
751 (25.4)1131 (30.1)996 (32.3)1299 (33.2)50-64
1032 (34.8)1220 (32.5)948 (30.7)1236 (31.6)65-79
440 (14.9)585 (15.6)409 (13.2)525 (13.4)≥80
Deprivation category
533 (18.0)449 (11.9)548 (17.7)448 (11.4)Most affluent
1255 (42.4)2684 (71.4)1298 (42.0)2745 (70.2)Intermediate
1174 (39.6)626 (16.7)1242 (40.2)720 (18.4)Most deprived
Tumour size (mm)
764 (52.3)*1090 (54.2)*——≤19
543 (37.2)*760 (37.8)*——20-39
153 (10.5)*161 (8.0)*——≥40
1502 (50.7)1748 (46.5)3088 (100)3913 (100)Not recorded
*Percentages calculated using number of patients with available data as the denominator.
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Table 2| Adjusted hazard ratios of mortality in the intervention area compared with the non-intervention area
All cause mortalityBreast cancer specific mortality
NPatient age group and time period of analysis PHazard ratio (95% CI)*PHazard ratio (95% CI)*
All cases
0.131.06 (0.98 to 1.14)0.041.11 (1.00 to 1.20)7001January 1990 to September 1995
0.0050.89 (0.82 to 0.97)<0.0010.82 (0.74 to 0.91)6721October 1995 to December 2000
0.003—<0.001—13 722Interaction between time period and area
Age ≤49 years
0.771.03 (0.85 to 1.25)0.631.05 (0.86 to 1.29)1588January 1990 to September 1995
0.311.13 (0.90 to 1.42)0.781.04 (0.81 to 1.32)1562October 1995 to December 2000
0.52—0.95—3150Interaction between time period and area
Age 50-64 years
0.031.18 (1.01 to 1.37)0.131.14 (0.96 to 1.34)2295January 1990 to September 1995
0.550.94 (0.78 to 1.14)0.420.92 (0.74 to 1.13)1882October 1995 to December 2000
0.07—0.11—4177Interaction between time period and area
Age 65-79 years
0.440.95 (0.83 to 1.08)0.971 (0.85 to 1.18)2184January 1990 to September 1995
0.050.87 (0.77 to 1.00)<0.0010.72 (0.60 to 0.85)2252October 1995 to December 2000
0.47—0.01—4436Interaction between time period and area
Age ≥80 years
0.331.08 (0.93 to 1.26)0.051.24 (1.00 to 1.56)934January 1990 to September 1995
0.0020.78 (0.67 to 0.91)0.010.75 (0.59 to 0.94)1025October 1995 to December 2000
0.002—0.001—1959Interaction between time period and area*
*Adjusted for year of incidence, deprivation, and (where appropriate) age.
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Figures
Fig 1 Five year survival by year of incidence with trends before and after year 1995, by intervention area
Fig 2 Funnel plot of breast cancer survival at five years in study hospitals, by time period. Hospitals diagnosing fewer than
25 patients in each time period were excluded (of which more than 75% diagnosed fewer than three cases of breast cancer)
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